Arming viruses in multi-mechanistic oncolytic viral therapy: current research and future developments, with emphasis...

Area of Science:

• Oncolytic virology
• Cancer therapy
• Viral vector engineering

Background:

• Oncolytic viruses replicate selectively in tumors, but monotherapy often yields limited responses.
• Combination regimens with chemotherapy, radiotherapy, or targeted therapies are crucial for efficacy, especially with smaller RNA viruses.
• Larger DNA viruses offer the capacity to express transgenes, enabling the integration of therapeutic functions directly into the viral vector.

Purpose of the Study:

• To review strategies for arming oncolytic viruses via transgene expression.
• To highlight the therapeutic potential of engineered oncolytic viruses.
• To focus on poxviruses as versatile platforms for oncolytic viral therapy.

Main Methods:

• Review of studies on transgene expression in oncolytic viruses.
• Focus on therapeutic mechanisms incorporated into viral vectors.
• Utilizing poxviruses as model systems for transgene delivery.

Main Results:

• Oncolytic viruses are most effective when combined with other cancer treatments.
• Transgene expression allows for the incorporation of immune activators, prodrug converting enzymes, anti-angiogenic factors, and stroma-targeting agents.
• Poxviruses serve as effective vectors for delivering therapeutic transgenes.

Conclusions:

• Engineering oncolytic viruses with transgenes significantly enhances their therapeutic capabilities.
• Combination strategies and viral vector design are key to advancing oncolytic virotherapy.
• Poxvirus-based vectors show promise for developing novel oncolytic viral therapies.